Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
Mitry E, Ducreux M, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouché O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P. Mitry E, et al. Among authors: ould kaci m. Gastroenterol Clin Biol. 2006 Mar;30(3):357-63. doi: 10.1016/s0399-8320(06)73188-8. Gastroenterol Clin Biol. 2006. PMID: 16633299 Free article. Clinical Trial.
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E, Amellal N, Farace F, Ould-Kaci M, Roux F, Marzin K, Soria JC. Bahleda R, et al. Among authors: ould kaci m. Br J Cancer. 2015 Nov 17;113(10):1413-20. doi: 10.1038/bjc.2015.374. Epub 2015 Oct 29. Br J Cancer. 2015. PMID: 26512876 Free PMC article. Clinical Trial.
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J; Subcutaneous Administration Propeukin Program Cooperative Group. Tourani JM, et al. J Clin Oncol. 2003 Nov 1;21(21):3987-94. doi: 10.1200/JCO.2003.02.073. J Clin Oncol. 2003. PMID: 14581421 Clinical Trial.
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H. Cortés J, et al. Among authors: ould kaci m. Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17. Lancet Oncol. 2015. PMID: 26596672 Clinical Trial.
15 results